About Neurocrine Biosciences
Neurocrine Biosciences (NBIX) develops and commercializes therapies for neurology and endocrine disorders. Neurocrine Biosciences’ Ingrezza became the first FDA-approved drug to be approved for the treatment of individuals with tardive dyskinesia. Neurocrine Biosciences’ Ingrezza competes with Teva Pharmaceutical’s (TEVA) Austedo in the tardive dyskinesia drugs market.
Orilissa also became the first FDA-approved drug for the management of endometriosis with moderate to severe pain. Neurocrine Biosciences and AbbVie entered into a collaboration for the development and commercialization of elagolix for women’s health. As part of this collaboration, AbbVie (ABBV) commercializes Orilissa.
On October 1, Neurocrine Biosciences (NBIX) announced that it would present new long-term clinical data on Ingrezza for the treatment of tardive dyskinesia. Neurocrine is scheduled to present this data at the International Congress of Parkinson’s Disease and Movement Disorders in Hong Kong from October 5 to 9.
Neurocrine Biosciences reported that it would present on the three long-term analyses, which evaluated the safety and efficacy of Ingrezza in individuals with TD. In the clinical trial, Ingrezza demonstrated symptomatic improvement and patient satisfaction.
On October 4, Neurocrine Biosciences (NBIX) stock closed at $114.58, which is an ~3.79% decline from its October 3 close of $119.09. Neurocrine Biosciences’ stock price increased 99.0% from its 52-week low of $57.71 on October 20, 2017, to reach $114.58 on October 4.
Neurocrine Biosciences’ stock price reached $114.58 on October 2 from $77.53 when the market opened on January 2, which represents ~48.0% YTD (year-to-date) growth. On September 13, NBIX stock hit its 52-week high of $126.98.
Of the 13 analysts tracking Neurocrine Biosciences (NBIX) in October, five recommended a “strong buy” while eight analysts recommended a “buy” rating. On October 4, Neurocrine Biosciences’ consensus 12-month target price was $134.46, which represents an ~17.35% return on investment over the next 12 months.